Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
I'm PortAI, I can summarize articles.
Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2026, maintaining its revenue guidance of $8-10 million for the year. The company has $22.3 million in pro forma cash and signed a letter of intent for XTL Biopharmaceuticals to acquire 85% of its subsidiary NeuroNOS, potentially yielding up to $32.5 million. Beyond Air is preparing for FDA clearance of its second-generation LungFit PH system and will present Phase 1a data from its UNO program at the AACR Annual Meeting in April 2026.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments